"Adenoviridae" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A family of non-enveloped viruses infecting mammals (MASTADENOVIRUS) and birds (AVIADENOVIRUS) or both (ATADENOVIRUS). Infections may be asymptomatic or result in a variety of diseases.
| Descriptor ID |
D000256
|
| MeSH Number(s) |
B04.280.030
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Adenoviridae".
Below are MeSH descriptors whose meaning is more specific than "Adenoviridae".
This graph shows the total number of publications written about "Adenoviridae" by people in this website by year, and whether "Adenoviridae" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 1 | 3 |
| 1996 | 6 | 1 | 7 |
| 1997 | 9 | 4 | 13 |
| 1998 | 9 | 3 | 12 |
| 1999 | 6 | 9 | 15 |
| 2000 | 10 | 7 | 17 |
| 2001 | 5 | 11 | 16 |
| 2002 | 8 | 10 | 18 |
| 2003 | 6 | 11 | 17 |
| 2004 | 13 | 11 | 24 |
| 2005 | 11 | 6 | 17 |
| 2006 | 6 | 9 | 15 |
| 2007 | 7 | 6 | 13 |
| 2008 | 6 | 6 | 12 |
| 2009 | 5 | 7 | 12 |
| 2010 | 7 | 3 | 10 |
| 2011 | 4 | 10 | 14 |
| 2012 | 8 | 3 | 11 |
| 2013 | 3 | 9 | 12 |
| 2014 | 3 | 7 | 10 |
| 2015 | 2 | 7 | 9 |
| 2016 | 3 | 4 | 7 |
| 2017 | 4 | 7 | 11 |
| 2018 | 2 | 5 | 7 |
| 2019 | 0 | 3 | 3 |
| 2020 | 4 | 0 | 4 |
| 2021 | 3 | 1 | 4 |
| 2022 | 0 | 4 | 4 |
| 2023 | 0 | 5 | 5 |
| 2024 | 2 | 3 | 5 |
| 2025 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Adenoviridae" by people in Profiles.
-
Integrating gene therapy into the treatment paradigm for non-muscle invasive bladder cancer. Expert Opin Biol Ther. 2025 Jan-Feb; 25(2):149-159.
-
Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma. J Immunother Cancer. 2025 Jan 04; 13(1).
-
Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity. J Immunother Cancer. 2024 Dec 09; 12(12).
-
Single-cell RNA sequencing analysis identifies acute changes in the tumor microenvironment induced by interferon a gene therapy in a murine bladder cancer model. Front Immunol. 2024; 15:1387229.
-
First-in-human clinical outcomes with NG-350A, an anti-CD40 expressing tumor-selective vector designed to remodel immunosuppressive tumor microenvironments. J Immunother Cancer. 2024 Oct 15; 12(10).
-
Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity. Int Immunopharmacol. 2024 Dec 05; 142(Pt A):113004.
-
Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors. J Immunother Cancer. 2024 Aug 28; 12(8).
-
The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models. Neuro Oncol. 2024 08 05; 26(8):1509-1525.
-
Hypothesis: AdAPT-001 and pseudoprogression - when seeing is not necessarily believing. J Immunother Cancer. 2024 Jun 17; 12(6).
-
Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial. Nat Med. 2024 Aug; 30(8):2216-2223.